Once in a while you can get shown the light in the strangest of places, if you look at it right.”
New research has shown that psychedelic-assisted therapy with micro doses of Psilocybin, the prodrug found in Magic Mushrooms for you Grateful Dead fans, can help with depression, alcohol use disorder, and nicotine addiction.
One study with Psilocybin has even received Breakthrough Therapy designation by the FDA for major depressive disorder.
While all these studies are legal, the federal government has not provided significant amounts funding for psychedelic research until late last year. Johns Hopkins just received the first federal grant for psychedelic treatment research in 50 years!
Matthew Johnson, professor of psychedelics and consciousness in the Department of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine, said:
“The historical importance of this grant is monumental.”
That might be an understatement.
The next step is for the FDA to approve Psilocybin for clinical use; there is hope that this will happen in the next 5 years.
With this in mind, the Heffter Research Institute provided a $900,000 grant that will help researchers from Johns Hopkins, Yale University, and New York University to build a postdoctoral fellowship and gold-standard training program in psychedelic therapy.
https://hub.jhu.edu/2022/09/07/new-era-of-psychedelic-treatment/
Let’s root for more federal funding, because this psilocybin light can shine bright on the darkness of depression and addiction and hopefully aiding in the Fentanyl epidemic we are facing.